United States Patent 6,274,171: Venlafaxine Extended-Release Formulation Scope, Validity, and Patent Landscape

US Patent 6,274,171 covers an encapsulated, once-daily venlafaxine hydrochloride formulation based on drug-loaded spheroids coated with ethyl cellulose and hydroxypropylmethylcellulose. Its strongest protection is directed to the formulation architecture and specified dissolution profile, not to venlafaxine hydrochloride itself. The patent was associated with Wyeth's Effexor XR product and is now expired, eliminating current U.S. infringement risk from the patent itself. Its historical importance remains material because it formed part of the patent barrier addressed by generic venlafaxine extended-release applicants.

What does US Patent 6,274,171 protect?

The patent protects a multiparticulate extended-release dosage form with four principal elements:

Venlafaxine hydrochloride as the active ingredient.
Spheroids containing venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose.
A release-controlling film coating containing ethyl cellulose and hydroxypropylmethylcellulose.
Encapsulation of the coated spheroids for oral, once-daily administration.

The independent formulation claim is claim 1. Claims 2 through 19 add quantitative, pharmacokinetic, dissolution, or material-specific limitations. Claims 20 through 25 are method-of-treatment claims.

The patent does not claim:

Venlafaxine hydrochloride as a chemical compound.
All extended-release venlafaxine formulations.
All capsules containing venlafaxine.
A generic oral dosage form without the claimed spheroid and coating structure.
A formulation using a different release-controlling polymer system unless it also satisfies the express claim limitations.

How broad is claim 1 of US 6,274,171?

Claim 1 is structurally broad relative to the narrower dependent claims, but it still contains multiple cumulative limitations. A potentially infringing product would need to satisfy each of the following requirements:

Claim 1 limitation	Required feature
Dosage form	Pharmaceutically acceptable capsule
Multiparticulate core	Spheroids
Active ingredient	Venlafaxine hydrochloride
Active concentration	About 6% to about 40% by weight
Diluent or matrix former	About 50% to about 94% microcrystalline cellulose, NF
Optional excipient	About 0.25% to about 1% hydroxypropylmethylcellulose
Release coating	Film coating
Coating polymers	Ethyl cellulose and hydroxypropylmethylcellulose

The claim uses "comprising," which generally makes it open-ended. A formulation may contain additional excipients and still fall within the claim if it contains the required elements. The open-ended transition does not eliminate the need to satisfy the claimed concentration ranges or the required polymer combination.

The term "about" creates a potential range-equivalence issue. A product slightly outside a numerical range may still be challenged under the doctrine of equivalents, although prosecution history, claim construction, and the importance of the numerical boundary would control.

What formulations are protected by the dependent claims?

The dependent claims divide the formulation estate into concentration and coating subgroups.

Higher-drug-load spheroids

Claims 4 and 5 cover spheroids containing:

30% to 40% venlafaxine hydrochloride;
50% to 70% microcrystalline cellulose;
Optional hydroxypropylmethylcellulose at 0.25% to 1%;
A coating containing 80% to 90% ethyl cellulose and 10% to 20% hydroxypropylmethylcellulose;
Total coating weight of 2% to 12%.

Claim 12 narrows the core composition to approximately:

37% venlafaxine hydrochloride;
0.5% hydroxypropylmethylcellulose;
62% microcrystalline cellulose.

Claim 19 is a highly specific commercial-style formulation claim requiring approximately:

37.3% venlafaxine hydrochloride;
62.17% microcrystalline cellulose;
0.5% hydroxypropylmethylcellulose;
A coating mixture of 85% ethyl cellulose and 15% hydroxypropylmethylcellulose;
The claimed dissolution profile.

Lower-drug-load spheroids

Claims 6 through 10 cover formulations with progressively lower venlafaxine concentrations:

Claims	Venlafaxine HCl	Microcrystalline cellulose
6-7	6% to 30%	70.1% to 94%
8	5% to 25%	75% to 95%
9	6% to 25%	75% to 94%
10	6% to 20%	80% to 94%

Claims 8 and 9 present a drafting issue. Claim 8 depends from claim 1 but recites a venlafaxine concentration as low as 5%, while claim 1 begins at approximately 6%. Claim 9 depends from claim 6 and begins at 6%, so it does not create the same apparent conflict. A court would ordinarily construe a dependent claim to include all limitations of the parent claim. As a result, the 5% lower boundary in claim 8 may have limited practical effect if it cannot be reconciled with claim 1.

Coating composition and material specifications

Claims 3, 5 and 7 require a film coating with:

80% to 90% ethyl cellulose;
10% to 20% hydroxypropylmethylcellulose;
2% to 12% coating by total formulation weight.

Claims 13 through 15 specify total coating quantities, including:

4.81% ethyl cellulose and 0.85% hydroxypropylmethylcellulose;
A total coating amount of 6% to 8%;
2.48% ethyl cellulose and 0.437% hydroxypropylmethylcellulose.

Claims 16 through 18 impose polymer-quality limitations. They require ethyl cellulose with approximately 44% to 51% ethoxy groups and hydroxypropylmethylcellulose with:

28% to 30% methoxy content;
7% to 12% hydroxypropoxy content.

Claim 18 also specifies viscosity parameters. These claims provide narrower positions that may have been useful in enforcement or prosecution, but they also make infringement dependent on analytical testing of the coating materials.

Does the patent require a specific dissolution profile?

Yes, claim 11 requires the following dissolution profile in USP Apparatus 1 at 100 rpm, using purified water at 37°C:

Time	Average venlafaxine HCl released
2 hours	Less than 30%
4 hours	30% to 55%
8 hours	55% to 80%
12 hours	65% to 90%
24 hours	More than 80%

Claim 19 repeats substantially the same dissolution limitation while adding a specific spheroid composition and an 85:15 ethyl cellulose/hydroxypropylmethylcellulose coating ratio.

This limitation is product-specific and testable. A generic manufacturer could potentially avoid claims 11 and 19 by using a different dissolution curve, although it would still need to avoid the broader structural claims.

Dissolution testing would raise several technical questions:

Whether the test uses the same basket apparatus and rotation speed;
Whether water is purified according to the applicable USP standard;
Whether testing is performed at 37°C;
Whether the percentage is calculated against labeled venlafaxine hydrochloride content;
Whether the reported value is an average and how individual units are treated;
Whether manufacturing variation causes batches to fall inside or outside the claimed ranges.

What do claims 20 through 25 cover?

Claims 20 through 25 cover methods for administering encapsulated extended-release venlafaxine hydrochloride to achieve:

Therapeutic plasma concentrations over 24 hours;
Reduced nausea and emesis;
A peak plasma concentration occurring approximately four to eight hours after administration;
A narrower peak interval of five to eight hours;
A peak at approximately six hours;
Reduction of peaks and troughs associated with multiple daily doses.

These claims are narrower from an enforcement perspective than the formulation claims because they require proof of administration and, in some cases, pharmacokinetic or clinical effects.

Claim 20 is the broadest method claim in this group because it specifies a four-to-eight-hour peak window. Claims 22 and 24 narrow the window to five-to-eight hours. Claims 23 and 25 narrow it further to approximately six hours.

The phrase "diminished incidences of nausea and emesis" creates an evidentiary issue. In an infringement action, the patent owner would need to establish that the claimed administration method produces the required clinical result or that the limitation is satisfied as a necessary property of the accused product and dosing regimen.

What was the FDA and Orange Book status of US 6,274,171?

US 6,274,171 was associated with Effexor XR, an extended-release venlafaxine hydrochloride product originally marketed by Wyeth, now within Pfizer's legacy product portfolio. Effexor XR received FDA approval for once-daily extended-release administration. The formulation was positioned to replace multiple daily doses of immediate-release venlafaxine with a once-daily capsule.

The relevant regulatory pathway for competing products was the abbreviated new drug application, or ANDA, rather than the 505(b)(2) pathway in most cases. Generic applicants were required to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.

The Orange Book historically listed patents covering Effexor XR, including formulation and related patent rights. Orange Book listings identify patents submitted by the NDA holder or sponsor, but listing does not establish validity or infringement. Patent expiration, pediatric exclusivity, certifications and litigation outcomes determine the practical barrier to generic approval.

Because US 6,274,171 has expired, it no longer creates a live Orange Book patent barrier to approval or launch. FDA approval of a current venlafaxine extended-release generic does not imply that the generic product would have been free of historical patent disputes at the time of its ANDA filing.

When did US Patent 6,274,171 lose exclusivity?

The patent's effective U.S. term ended in 2020, based on the patent term applicable to the underlying application and reported patent-term adjustment. The operative expiration date is generally reported as June 13, 2020. Any pediatric exclusivity must be evaluated separately from the base patent term and the specific Orange Book record.

The patent is therefore expired as of 2026. No new U.S. formulation product can rely on this patent for an enforceable exclusion right, and a current generic manufacturer does not face prospective infringement liability based solely on practicing the expired claims.

Event	Date or period
Priority and application activity	Late 1990s
U.S. patent issuance	August 14, 2001
Product association	Effexor XR, venlafaxine hydrochloride extended release
Historical generic challenge period	Mid-to-late 2000s
Reported patent expiration	June 13, 2020
Current status	Expired

Which companies challenged the Effexor XR patent estate?

The principal commercial challenge came from generic applicants seeking approval for venlafaxine hydrochloride extended-release capsules. Teva was among the prominent ANDA applicants involved in the historical patent disputes concerning Effexor XR. Other generic manufacturers, including Mylan and later companies operating through the Viatris portfolio, competed in the same product category.

An ANDA applicant challenging an Orange Book-listed patent typically uses one of four certifications:

Paragraph I: no patent information is listed;
Paragraph II: the listed patent has expired;
Paragraph III: the applicant will wait until expiration;
Paragraph IV: the patent is invalid, unenforceable or will not be infringed.

Paragraph IV certification creates the statutory basis for patent litigation after notice to the NDA holder. The patent disputes involving Effexor XR were part of the broader generic-entry process for venlafaxine extended-release capsules.

The commercial impact of a Paragraph IV challenge depended on whether the NDA holder filed suit within the statutory period, whether a 30-month stay applied, whether the patent survived invalidity and noninfringement defenses, and whether the parties settled.

What patent litigation affected venlafaxine extended-release generics?

The historical litigation focused on whether generic extended-release venlafaxine products practiced the claimed spheroid formulation and whether the asserted claims were valid and infringed. The main legal issues included:

Obviousness based on known controlled-release multiparticulate systems;
The predictability of combining venlafaxine hydrochloride with microcrystalline cellulose;
The use of ethyl cellulose and hydroxypropylmethylcellulose as release-controlling polymers;
Whether the claimed dissolution profile represented an inventive result;
Whether the ANDA product contained the claimed percentages and coating composition;
The enforceability of method claims directed to plasma profiles and reduced adverse effects.

The strongest defense against the broad formulation claims would be an obviousness case based on prior art disclosing:

Venlafaxine hydrochloride;
Once-daily or extended-release oral dosage forms;
Drug-loaded pellets or spheroids;
Microcrystalline cellulose cores;
Ethyl cellulose coatings;
Hydroxypropylmethylcellulose as a pore former, binder or coating component.

The patent owner's strongest position would be the combination of specific composition ranges, coating ratios, and dissolution behavior, particularly if the prior art did not provide a reasonable expectation of achieving the claimed 24-hour release profile.

How strong was the patent estate for Effexor XR?

The estate was commercially meaningful but technically concentrated. Its protection was strongest against products that copied the same multiparticulate design.

Estate characteristic	Assessment
Active ingredient protection	Weak or absent; venlafaxine was not claimed as a compound
Formulation protection	Strongest area
Spheroid architecture	Central limitation
Polymer combination	Important narrowing feature
Dissolution profile	Strong evidentiary limitation but design-around opportunity
Pharmacokinetic claims	Potentially useful but harder to enforce
Method claims	Dependent on proof of administration and clinical effect
Current exclusionary value	None after expiration

The patent's commercial value came from the difficulty of developing a bioequivalent extended-release product, not from broad exclusivity over venlafaxine. A generic applicant could avoid infringement by changing the release technology, using a different polymer system, changing the multiparticulate structure, or developing an equivalent product that did not meet the claimed numerical limitations.

What manufacturing and intellectual-property barriers did the patent create?

The formulation requires control over several manufacturing variables:

Spheroid size and density;
Distribution of venlafaxine hydrochloride within the cores;
Microcrystalline cellulose grade and moisture content;
Hydroxypropylmethylcellulose level;
Ethyl cellulose substitution and viscosity;
Hydroxypropylmethylcellulose substitution and viscosity;
Coating weight gain;
Coating uniformity;
Final dissolution behavior.

These variables create process-development and scale-up barriers even where a product is designed to avoid literal infringement. A formulation can avoid the patent yet fail bioequivalence or exhibit unacceptable batch-to-batch release variation.

The patent also creates an analytical risk. Coating percentages may be measured against total formulation weight, while active and excipient percentages may be calculated against spheroid weight. A manufacturer needs consistent basis-of-calculation rules when comparing its product with the claim language.

Were there licensing deals or settlement agreements tied to this patent?

The principal commercial mechanism was generic ANDA litigation and settlement rather than a widely documented standalone license of US 6,274,171. Generic market entry could occur through:

A settlement permitting launch before patent expiration;
A finding of invalidity or noninfringement;
Expiration of the patent;
A negotiated license or supply arrangement;
An authorized generic strategy.

Public patent records and FDA approval records should be distinguished from confidential settlement terms. A generic approval date alone does not establish whether entry resulted from a license, a court ruling, a settlement or expiration of the relevant patent rights.

How does US 6,274,171 compare with later venlafaxine patents?

US 6,274,171 is the foundational formulation patent in the Effexor XR estate. Later patents generally added or refined protection around related formulations, manufacturing parameters, dosage strengths, coating systems, or product-specific features.

Patent category	Typical protection
Foundational formulation patent	Spheroids, venlafaxine HCl, microcrystalline cellulose, polymer coating
Follow-on formulation patents	Narrower composition, coating or release parameters
Manufacturing patents	Pellet formation, coating process or scale-up controls
Method patents	Once-daily dosing, plasma profile or adverse-effect reduction
Regulatory patents	Patents listed against the reference product for ANDA certification

A freedom-to-operate review cannot stop with US 6,274,171. A product that avoids this patent may still have been exposed historically to continuation, divisional or related patents in the Effexor XR estate. Those related rights must be reviewed by claim family, jurisdiction, expiration date and asserted status.

What generic launch scenarios existed for venlafaxine extended-release capsules?

The principal launch scenarios were:

Early Paragraph IV launch

A first applicant could seek 180-day generic exclusivity after a qualifying Paragraph IV challenge, subject to FDA eligibility rules and litigation outcomes. This scenario created substantial commercial value because venlafaxine extended-release capsules had an established branded market and a relatively limited number of early competitors.

At-risk launch

A generic company could launch before final resolution of all patent issues, accepting potential damages exposure if the patent were later upheld and found infringed. The commercial decision would depend on expected damages, injunction risk, market share and the strength of invalidity arguments.

Settlement-based launch

The parties could agree to an authorized or licensed launch date before patent expiration. Settlement terms could include restrictions on launch timing, supply arrangements or non-exclusive entry.

Post-expiration launch

After June 2020, the patent no longer constrained launch. Competition then depended primarily on FDA approval, manufacturing capacity, reimbursement and the number of approved ANDAs.

Is there biosimilar risk for venlafaxine?

No. Venlafaxine hydrochloride is a synthetic small-molecule drug, not a biologic. The relevant competitors are generic ANDA applicants, not biosimilar applicants under the Public Health Service Act.

The principal regulatory and commercial issues are:

ANDA approval;
Pharmaceutical equivalence;
Bioequivalence;
Extended-release dissolution performance;
Manufacturing consistency;
Labeling and dosage strength;
State substitution and payer contracting.

Key Takeaways

US 6,274,171 covers a specific venlafaxine hydrochloride extended-release capsule using drug-loaded spheroids and an ethyl cellulose/hydroxypropylmethylcellulose coating.
Claim 1 is the central formulation claim. It requires all listed structural and compositional elements.
Claims 11 and 19 add a detailed 24-hour dissolution profile and are narrower but more objectively testable.
Claims 20 through 25 cover once-daily treatment methods linked to plasma levels, reduced peaks and troughs, and reduced nausea or emesis.
Claim 8 contains an apparent dependency and numerical-range inconsistency because it recites 5% venlafaxine while depending from claim 1, which begins at approximately 6%.
The patent's strength was concentrated in its multiparticulate formulation design and manufacturing-specific parameters.
The patent did not provide compound-level exclusivity over venlafaxine.
Historical Paragraph IV litigation involved generic venlafaxine extended-release applicants, including Teva.
The patent expired in 2020 and has no current U.S. exclusionary value.
Current market entry is governed by FDA ANDA requirements and any surviving related patents, not by US 6,274,171.

Frequently Asked Questions

Can a venlafaxine extended-release tablet infringe US 6,274,171?

Usually not literally, because the patent requires a pharmaceutically acceptable capsule containing spheroids. A tablet could still raise an equivalents argument, but its different dosage-form structure would provide a substantial noninfringement position.

Does using ethyl cellulose alone avoid the patent?

It would avoid the literal requirement for a coating containing both ethyl cellulose and hydroxypropylmethylcellulose. The product would still require review against other patents and possible doctrine-of-equivalents theories.

Does a product need to match the claimed six-hour peak to infringe the formulation claims?

No. The six-hour peak limitation appears in method claims 23 and 25, not in the basic formulation claim 1. A product could potentially satisfy a formulation claim without producing the specific claimed pharmacokinetic peak.

Can a generic use a different spheroid drug concentration?

Yes, if its formulation falls outside the applicable claim ranges and does not meet the remaining limitations under literal infringement or the doctrine of equivalents. The concentration must be assessed on the same weight basis used in the claim.

Does patent expiration remove FDA bioequivalence requirements?

No. Expiration removes the patent exclusion right but does not eliminate FDA requirements for an ANDA, including pharmaceutical equivalence, bioequivalence, quality controls and approved labeling.

References

U.S. Patent and Trademark Office. (2001). U.S. Patent No. 6,274,171: Extended release formulation of venlafaxine hydrochloride.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
U.S. Food and Drug Administration. (2023). Effexor XR (venlafaxine hydrochloride) extended-release capsules prescribing information. Pfizer.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Venlafaxine hydrochloride extended-release capsules.
U.S. Court of Appeals for the Federal Circuit. (2009). Wyeth v. Sandoz, Inc., patent litigation concerning venlafaxine extended-release formulations.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	006519	⤷ Start Trial
Argentina	014012	⤷ Start Trial
Austria	237320	⤷ Start Trial
Austria	257011	⤷ Start Trial
Australia	1300399	⤷ Start Trial
Australia	1640097	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,274,171

Summary for Patent: 6,274,171